Last reviewed · How we verify

NCT06346795

Class II Restorations With High-Filled Flowable Composites

Not yet recruiting NA Last updated 25 April 2024
What this trial tests

NA trial testing High-filling flowable dental composite in Dental Caries in 60 participants. Not yet recruiting.

Timeline
1 June 2024
Primary endpoint
1 December 2024
1 June 2025

Quick facts

Lead sponsorSelcuk University
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposetreatment
Enrollment60
Start date1 June 2024
Primary completion1 December 2024
Estimated completion1 June 2025
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Selcuk University

Who can join

Adults 18 to 50, any sex, with Dental Caries or Class II Dental Caries. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In the study, Class II restorations will be performed with G-aenial Universal Injectable (GC/ Tokyo, Japan), Grandio Flow (VOCO/ Germany), and Clearfil Majesty Flow (Kuraray/ Japan) composites will evaluated. Restorations will be assessed according to modified USPHS criteria in 1st week, 6th months, and 12th months from the placement date. The Chi-square test will used for statistical analysis of the difference between the groups, and the Cochran Q test will used for the significance of the difference between time-dependent changes within each group (p\<0.05).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Dental Caries

Currently open trials in the same condition.

Other Selcuk University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06346795.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing